Lexicon Pharmaceuticals, Inc. The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of Texas on behalf of investors who purchased Lexicon Pharmaceuticals, Inc. (NASDAQGS: LXRX) securities between March 11, 2016 and January 17, 2019.
According to the Lexicon lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the data from Lexicon’s Phase 3 clinical trials assessing the safety and efficacy of Sotagliflozin in treating type 1 diabetes were not as positive as Lexicon represented; (ii) the health risks posed by Sotagliflozin were severe enough to threaten its U.S. Food & Drug Administration approval prospects; and (iii) as a result, Lexicon’s public statements were materially false and misleading at all relevant times.
“Lexicon Pharmaceuticals, Inc.”
If you suffered a loss in Lexicon you have until April 1, 2019 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
To receive more information, please fill out the form.